ReviewCurrent allergy and asthma reports2006
Suppressor of cytokine signaling 3 (SOCS3) in Th2 cells evokes Th2 cytokines, IgE, and eosinophilia.
Review in Current allergy and asthma reports, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 51 citations in OpenAlex.
- Expression and correlation of SOCS3 and Eotaxin mRNA and proteins levels in nasal mucosal tissue of allergic rhinitis patients.Frontiers in immunology · 2025Article
- Expression of PSMD14 in lung adenocarcinoma and its impact on immune cell infiltration and prognosis: a comprehensive analysis based on RNA and single-cell RNA sequencing.Frontiers in immunology · 2025Article
- SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation.Frontiers in immunology · 2024Review
- Tissue levels of suppressor of cytokine signaling-3 (SOCS-3) in mycosis fungoides.Archives of dermatological research · 2023Article
- MicroRNA expression profile of chicken cecum in different stages during Histomonas meleagridis infection.BMC veterinary research · 2022Article
- A review of epigenetic changes in asthma: methylation and acetylation.Clinical epigenetics · 2021Review
- Resident alveolar macrophage-derived vesicular SOCS3 dampens allergic airway inflammation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo.Cell cycle (Georgetown, Tex.) · 2020Review
- New perspectives on the regulation of type II inflammation in asthma.F1000Research · 2017Review
- IL-10 and socs3 Are Predictive Biomarkers of Dengue Hemorrhagic Fever.Mediators of inflammation · 2017Article
- Delivery of RNAi Therapeutics to the Airways-From Bench to Bedside.Molecules (Basel, Switzerland) · 2016Review
- Methylation and microRNA-mediated epigenetic regulation of SOCS3.Molecular biology reports · 2015Article
- SOCS3 silencing attenuates eosinophil functions in asthma patients.International journal of molecular sciences · 2015Article
- Genetic correlation of SOCS3 polymorphisms with infantile asthma: an evidence based on a case-control study.International journal of clinical and experimental pathology · 2015Article
- Molecular biology of atopic dermatitis.Clinical reviews in allergy & immunology · 2014Review
- The signaling suppressor CIS controls proallergic T cell development and allergic airway inflammation.Nature immunology · 2013Article
- Purification and identification of an IgE suppressor from strawberry in an in vitro immunization system.Cytotechnology · 2012Article
- SOCS2 regulates T helper type 2 differentiation and the generation of type 2 allergic responses.The Journal of experimental medicine · 2011Article
- Suppressors of cytokine signaling 3 expression in eosinophils: regulation by PGE₂ and Th2 cytokines.Clinical & developmental immunology · 2011Article
- Gene expression profiling in lungs of chronic asthmatic mice treated with galectin-3: downregulation of inflammatory and regulatory genes.Mediators of inflammation · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis, allergic rhinitis, and bronchial asthma are allergic immune disorders characterized by a predominance of T helper 2 (Th2) cells, the resulting elevation of allergen-specific immunoglobulin E (IgE), and mast cell- and eosinophil-associated inflammation. The cytokine environment at the site of the initial antigen stimulation determines the direction of helper T-cell differentiation into Th1 or Th2 cells. Therefore, negative regulators of cytokine signaling, suppressors of cytokine signaling (SOCS) proteins, play an important role in Th2-mediated allergic responses through the control of the balance between Th1 and Th2 cells. SOCS3 and SOCS5 are predominantly expressed in Th2 and Th1 cells, respectively, and they reciprocally inhibit the Th1 and Th2 differentiation processes. In this article, we discuss the role of SOCS3 and SOCS5 proteins in atopic asthma and allergic conjunctivitis and explore the potential of SOCS proteins as targets for therapeutic strategies in allergic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.